Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta

Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)

Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study

Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin

Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study